机构：[1]Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]State Key Laboratory of Respiratory Health and Multimorbidity, Chengdu, China.[3]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[4]The Research Units of West China, Chinses Academy of Medical Sciences, West China Hospital, Chengdu, China.四川大学华西医院[5]Institute of Respiratory Health Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院
Lung cancer has maintained a high prevalence and mortality. Besides, venous thromboembolism (VTE) is the third most common disease of cardiovascular disease. Lung cancer with VTE usually influenced the overall survival in the follow-up. In the development of lung cancer, vigilance against and early diagnosis of VTE is of significance.We searched the databases of PubMed, Web of Science, Embase and Cochrane for related research up to 30 November 2023 and extracted information of incidence, odds ratio (OR), hazard ratio (HR) and their 95% confidence intervals (CIs), for evaluating the incidence of VTE and its risk factors.A total of 54 articles and 873,292 records were included in our study. The pooled incidences of VTE and PE were 6% and 3%, respectively. Subgroup analysis revealed that the tumour, node and metastasis (TNM) stage (HR= 5.43, 95% CI: 2.42, 12.22), metastasis (HR= 2.67, 95% CI: 1.35, 5.29) and chemotherapy (HR= 2.27, 95% CI: 1.11, 4.65) had major influence on VTE occurrence.Lung cancer complicated with VTE is unignorable, and its occurrence varies widely by tumour staging, tissue type and treatment. The results may aid in clinical decision-making about lung cancer in higher risk with VTE and weather receiving anticoagulant prophylaxis.
基金：
The work was supported by the National Natural Science
Foundation of China under Grant number 92159302, the
Science and Technology Project of Sichuan under Grant
number 2022ZDZX0018.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|2 区医学
小类|2 区医学：内科
第一作者：
第一作者机构：[1]Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.[2]State Key Laboratory of Respiratory Health and Multimorbidity, Chengdu, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.[2]State Key Laboratory of Respiratory Health and Multimorbidity, Chengdu, China.[3]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.[4]The Research Units of West China, Chinses Academy of Medical Sciences, West China Hospital, Chengdu, China.[5]Institute of Respiratory Health Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.[*1]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, Sichuan 610041, China.
推荐引用方式(GB/T 7714)：
Yang Ruiyuan,Wang Haoyu,Liu Dan,et al.Incidence and risk factors of VTE in lung cancer: a meta-analysis[J].Annals Of Medicine.2024,56(1):2390200.doi:10.1080/07853890.2024.2390200.
APA：
Yang Ruiyuan,Wang Haoyu,Liu Dan&Li Weimin.(2024).Incidence and risk factors of VTE in lung cancer: a meta-analysis.Annals Of Medicine,56,(1)
MLA：
Yang Ruiyuan,et al."Incidence and risk factors of VTE in lung cancer: a meta-analysis".Annals Of Medicine 56..1(2024):2390200
